Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Clinical Pharmacogenetics Implementation Consortium guidelines for human leukocyte antigen-B genotype and allopurinol dosing.

Clinical pharmacology and therapeutics - 1 Feb 2013

Hershfield M S, Callaghan J T, Tassaneeyakul W, Mushiroda T, Thorn C F, Klein T E, Lee M T M

Abstract excerpt

Allopurinol is the most commonly used drug for the treatment of hyperuricemia and gout. However, allopurinol is also one of the most common causes of severe cutaneous adverse reactions (SCARs), which include drug hypersensitivity syndrome, Stevens–Johnson syndrome, and toxic epidermal necrolysis. A variant allele of the human leukocyte antigen (HLA)-B, HLA-B*58:01, associates strongly with allopurinolinduced...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Allopurinol
Share to Dose-Response Relationship, Drug

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Gout Suppressants

Share to HLA-B Antigens

Share to Hyperuricemia

Share to Pharmacogenetics

Share to Stevens-Johnson Syndrome

Source

Open in PubMed Open full text

Identifiers

PMID: 23232549
DOI: 10.1038/clpt.2012.209
PMCID: PMC3564416

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Clinical Pharmacogenetics Implementation Consortium guidelines for human leukocyte antigen-B genotype and allopurinol dosing.PMID 23232549Read ↗

Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for human leukocyte antigen B (HLA-B) genotype and allopurinol dosing: 2015 update.Semantic proximity Read ↗

Genetic markers associated with cutaneous adverse drug reactions to allopurinol: a systematic review.Semantic proximity Read ↗

Pharmacogenetics of allopurinol--making an old drug safer.Semantic proximity Read ↗

Impact of HLA-B*58:01 allele and allopurinol-induced cutaneous adverse drug reactions: evidence from 21 pharmacogenetic studies.Semantic proximity Read ↗

HLA-B*58:01 is an Incomplete Predictor of Allopurinol-Induced Severe Cutaneous Adverse ReactionsSemantic proximity Read ↗

Clinical pharmacogenetics implementation consortium guidelines for HLA-B genotype and abacavir dosing.Semantic proximity Read ↗

HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol.Semantic proximity Read ↗

Tailoring of recommendations to reduce serious cutaneous adverse drug reactions: a pharmacogenomics approach.Semantic proximity Read ↗

Clinical Pharmacogenetics Implementation Consortium guidelines for HLA-B genotype and carbamazepine dosing.Semantic proximity Read ↗

Impact of the HLA-B(*)58:01 Allele and Renal Impairment on Allopurinol-Induced Cutaneous Adverse Reactions.Semantic proximity Read ↗

Human leukocyte antigen (HLA) pharmacogenomic tests: potential and pitfalls.Semantic proximity Read ↗

Immunopathogenesis and risk factors for allopurinol severe cutaneous adverse reactions.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.